Logo

Stilla Technologies: Khaled Bahi, Jerome Leclercq, Quang Tran

Dec 11, 2019

Stilla Technologies has added Khaled Bahi as chief financial officer, Jerome Leclercq as senior vice president for commercial operations Europe and Asia, and Quang Tran as quality and regulatory affairs director.

Bahi has more than 20 years of experience in the medtech industry in finance and operations roles, previously serving as CFO of the Swiss cardiovascular company Symetis, which was acquired by Boston Scientific. Leclercq has more than 30 years of experience in the commercialization of advanced technologies in the life sciences and previously held senior positions at Gilson and PerkinElmer. Tran has more than 20 years experience in the medtech and biotech industries in quality, regulatory, and operating roles, with previous positions at BioSerenity and Becton Dickinson, among others.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.